Ask an exporter how Iraq works and you will usually get one of two wrong answers: that everything goes through government tender, or that you simply appoint a distributor like anywhere else. Neither is right. The Iraqi Ministry of Health operates a dedicated state company for the importation and marketing of medicines and medical appliances, KIMADIA, and alongside it the private-sector channel runs through registered scientific offices. This is what the desk at M Care Exports understands about how the two routes differ and where files fail.
What KIMADIA is, and what it is not.
KIMADIA, the State Company for Marketing Drugs and Medical Appliances, sits under the Iraqi Ministry of Health and is responsible for importing and distributing medicines and medical appliances for the public health facilities. In practical terms it is the buying counter for the public system: the hospitals, the directorates of health, the public supply chain, and it buys through a tender system.
What it is not is a registration authority in the sense a European exporter might assume. Product registration and the issuing of import licences sit within the Ministry of Health's regulatory apparatus. KIMADIA is the procurement side. Confusing the two produces the most common opening mistake on Iraqi enquiries, which is a supplier sending a catalogue to a procurement body for a product that has no Iraqi regulatory standing at all.
For a buyer, the useful consequence is that a KIMADIA award and a marketing authorisation are separate things you need separately. Neither substitutes for the other.
The scientific office, and why it exists.
The standard route for a foreign manufacturer into the Iraqi private sector is through a registered scientific office. The scientific office is a locally registered entity that represents the foreign manufacturer, carries the regulatory relationship and handles the in-country commercial function.
Two things about the scientific office are worth stating precisely, because exporters routinely get them backwards.
- It is the standard path, not the only one. KIMADIA retains authority to deal directly with non-Iraqi manufacturers and marketers as an exception, where it considers that necessary. So a manufacturer being told that a particular office is the only possible way in should treat that as a commercial assertion rather than a statement of law.
- It is a representation relationship, with the leverage that implies. The office holds the local standing. As with any agency structure, the terms on which you enter it determine how easily you can leave it. Negotiate the exit before you need it.
An importer evaluating an Indian supplier should ask which scientific office represents them, whether that representation is exclusive, and whether the products they are quoting are actually attached to that representation or merely available in the supplier's catalogue.
Two registrations, not one.
Here is the gate that catches exporters who have worked elsewhere in the region. In Iraq both the manufacturer and the product must be registered with the Ministry of Health before an import licence can be granted. Not the product alone. The manufacturing entity carries its own registration status, and a product from an unregistered manufacturer does not become importable because the product file is in good order.
The sequencing consequence is significant. If you are a buyer evaluating an Indian supplier for the Iraqi market, the question is not only whether the molecule is registered but whether that specific manufacturer is. Two suppliers can offer the same molecule at the same strength and only one of them can actually be imported, because only one of the manufacturing sites carries Iraqi registration.
It also means manufacturer changes are expensive. Switching the source of an already-registered product is not a paperwork amendment you can do between shipments. Plan supply continuity around the registered site rather than around the lowest quote of the quarter.
Document legalisation, the step that stops everything.
The requirement that most often halts an Iraqi file is not clinical or technical. It is documentary. Company and product documents must be properly legalised and stamped, and without that the Ministry of Health does not issue an import licence at all.
The word to hold onto is precondition. This is not a scoring criterion that costs you points on a bid; it is a gate that determines whether a licence is issued in the first place. Certificates of pharmaceutical product, free sale certificates, GMP certificates and company registration documents typically pass through a chain of attestation before they are acceptable, and each link in that chain has its own turnaround.
The practical failure mode is sequencing. Exporters commission legalisation after an order looks likely, discover the chain takes longer than the buyer's patience, and lose the order to a supplier whose paperwork was already attested. On active markets we prepare the attested set in advance rather than on demand, precisely because the chain cannot be compressed once it has started.
Reading which route you are actually in.
Before quoting anything into Iraq, establish the channel. The questions that resolve it quickly:
- Is the ultimate buyer a public hospital or directorate, or a private importer, pharmacy chain or hospital group?
- Is there an existing scientific office representing the manufacturer for this product, and is the product registered in Iraq?
- Is the enquiry referencing a KIMADIA tender number, or is it a commercial purchase order?
- Who is named as the importer of record, and do they hold the licence for this product?
- Are the company and product documents already legalised, and to what date?
Those five answers determine the structure of the deal, the paperwork you need and who carries the regulatory risk. An enquiry that cannot answer them is not yet a deal; it is an introduction.
Where a merchant-exporter fits.
We supply from the Indian side. That means selecting manufacturing partners whose documentation will survive Iraqi attestation, supplying the certificate of pharmaceutical product and GMP certificate from WHO-GMP certified Indian manufacturers, preparing the batch and stability documentation, and keeping supply continuous once a product has standing in the market.
We are not your scientific office, we are not the importer of record in Iraq, and we do not bid to KIMADIA on your behalf. Those roles belong to Iraqi-resident entities. Saying so plainly saves both sides a conversation that would otherwise happen three weeks into a file.
Frequently asked
What is KIMADIA?
KIMADIA is the state company under the Iraqi Ministry of Health responsible for the importation and marketing of medicines and medical appliances. It is the buying counter for the public health system. It is a procurement body, not the registration authority, so a KIMADIA award does not substitute for the product having Iraqi regulatory standing.
Does the manufacturer need to be registered in Iraq, or just the product?
Both. In Iraq the manufacturer and the product must each be registered with the Ministry of Health before an import licence can be granted. A well-prepared product file does not make a product importable if the manufacturing site itself is not registered, which is why two suppliers can quote the same molecule and only one can actually ship.
Does a foreign manufacturer have to work through a scientific office in Iraq?
The scientific office is the standard route for the private sector, and for most foreign manufacturers it is how the market is entered. It is not an absolute rule: KIMADIA retains authority to deal directly with non-Iraqi manufacturers and marketers as an exception where it considers that necessary.
Why do Iraqi files stall on documentation?
Because legalisation is a precondition rather than a preference. Company and product documents must be properly legalised and stamped, and without that the Ministry of Health does not issue an import licence at all. The attestation chain takes time that cannot be compressed once an order is already on the table.
Is a KIMADIA tender the same as a private import order?
No, and treating them the same is a common error. A KIMADIA tender is public-sector procurement with its own submission mechanics and counterparty. A private order runs through the commercial channel, typically involving a scientific office and a licensed importer. The paperwork, the risk and the contracting party all differ.
Can M Care Exports bid into KIMADIA directly?
No. We are an Indian merchant-exporter, not an Iraqi-resident entity, so we are neither a scientific office nor an importer of record in Iraq. We supply the product and the manufacturer-side documentation to the party that holds those roles.
What should an Iraqi importer ask an Indian supplier first?
Which scientific office represents them, whether the specific product is registered in Iraq and attached to that representation, and whether the company and product documents are already legalised and to what date. A supplier who cannot answer those has a catalogue rather than a market position.
Send the specifics. We will scope it honestly.
Molecule, strength, volume and destination. The Mumbai desk replies within one working day, including when the answer is that the route is not viable yet.